Quintero BM, Domínguez BN, Rodríguez MS, Linares GM, Denis GD, Bueno AY

Language: Spanish
References: 14
Page: 536-541
PDF size: 394.79 Kb.

ABSTRACT

Chloroquine-induced toxic maculopathy and visual rehabilitation through the use of microperimeter MP1. Chrloroquine is a drug that may cause visual dysfunctions, low vision and even blindness depending on dose. An accumulative dose lower than 100 g of chloroquine or a length of treatment less than one year is rarely associated to retinal injure. The toxicity risk increases when the accumulative dose exceeds 300 g (250mg/day for 3 years). This drug is used in treating autoimmune diseases. Here is the case of a 44 years-old patient, with history of rheumatoid arthritis for 14 years. Chloroquine treatment was indicated (one 250 mg tablet daily) at the time of initial diagnosis. Five years ago, he was diagnosed with chloroquine-induced maculopathy when he went to the doctor's because of low vision and asked for possible visual rehabilitation. An ophthalmologic exam, some supplementary studies and rehabilitation through the microperimeter MP1 were all performed. It was concluded that chloroquine-maculopathy with microperimetry provides improvement of several visual parameters and better visual quality for the patient.

REFERENCES

1. Da Silva Alves N. Maculopatía Tóxica por cloroquina. Rev Bras Oftalmol. 2009;68(3):161-7.

2. Biccas Neto L, Mesquita AS. Toxic maculopathy caused by antimalarial drugs: dectection using spectral domain OCT: case reports. Arq Bras Oftalmol. 2009;72(5):710-4.

3. Berholz R, Schroeter J, Ruther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol. 2010;94(12):1637-42.

4. Riordan-Eva P, Whitcher JP. Vaughan and Ashury´s General Ophthalmology. 17 ed. USA:Mc Graw- Hill Companies; 2008.

5. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recomendation on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-22.

6. Hanna B, Holdeman NR, Tang RA, Schiffman JS. Retinal toxicity secondary to plaquenil theraphy. Optometry. 2008;79(2):90-4.

7. Tarita-Nistor L, González Esther G, Markowitz SN, Steinbach MJ. Plasticity of fixation in patients with central vision loss. Vis Neurosci. 2009;26(5-6):487-94.

8. Greenstein VC, Santos RA, Tsang SH, Smith RT, Barile GR, Seiple W. Preferred retinal locus in macular disease: characteristics and clinical implications. Retina. 2008;28(9):1234-40

9. Korah S, Kuriakose T. Optical Coherence tomography in a patient with chloroquine induced maculopathy. Indian J Ophthalmol. 2008;56(6):511-3

10. American Academy of Ophthalmology. Part lll. Cap 4: Acquired Diseases Affecting the Macula. En :Retina and Vitreous. USA:American Academy of Ophthalmologyy 2008.(Basic and Clinical Science course :12). Pp.55-9.

11. Giorgi D, Contestabile MT, Pacella E, Gabrieli CB. An instrument for biofeedback applied to vision. Applied Psychophysiology Biofeedback. 2005;30(4):38995.

12. Contestabile MT, Recupero SM, Palladino D, De Stefanis M, Abdolrahimzadeh S, Suppressa F, et al. A new method of biofeedback in the management of low vision. Eye. 2002;16(4):47280.

13. Buia C, Tiesinga P. Attentional modulation of firing rate and synchrony in a model cortical network. J Comput Neurosci. 2006;20(3):24764.

14. Vingolo EM, Salvatore S, Cavarretta S. Low-vision rehabilitation by means of MP-1 biofeedback examination in patients with different macular diseases: A pilot study. Appl Psychophysiol Biofeedback. 2009;34(2):127-33.